C-cyclopropyl-C-thiophen-2-yl-methylamine | 473732-80-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: C-cyclopropyl-C-thiophen-2-yl-methylamine
• 英文别名: 1-(2-thienyl)cyclopropylmethylamine；1-(thien-2-yl)cyclopropylmethylamine；1-Cyclopropyl-1-thien-2-ylmethanamine；cyclopropyl(thiophen-2-yl)methanamine
• CAS: 473732-80-8
• 化学式: C₈H₁₁NS
• mdl: MFCD05191949
• 分子量: 153.248
• InChiKey: AAQQXHHWWFZBRH-UHFFFAOYSA-N

物化性质

• 沸点：
  248.0±15.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  54.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-噻酚基环丙基甲酮 、 、 氰基硼氢化钠 以 甲醇 为溶剂， 以to give cyclopropyl(thiophen-2-yl)methanamine (colorless oil, 876 mg, 42%)的产率得到C-cyclopropyl-C-thiophen-2-yl-methylamine
  参考文献：
  名称：

  KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

  摘要：

  本文提供了一种由结构式（I）表示的化合物，或其药学上可接受的盐。还描述了这些药物组合物的制备方法和使用方法。

  公开号：

  US20140051679A1

文献信息

• [EN] INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME<br/>[FR] COMPOSÉS INDAZOLE UTILISÉS COMME INHIBITEURS DE KINASE ET MÉTHODE DE TRAITEMENT DU CANCER AVEC LESDITS COMPOSÉS
  申请人：UNIV HEALTH NETWORK

  公开号：WO2013053051A1

  公开（公告）日：2013-04-18

  The present teaching provide indazole compounds represented by Structural Formulae (I) or (I') or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as TTK protein kinase, polo-like kinase 4 (PLK4) and Aurora kinases having anticancer activity against breast cancer cells, colon cancer cells, and ovarian cancer cells.

  本教学提供了由结构式（I）或（I'）表示的吲唑化合物或其药用可接受的盐。还描述了这些药物组合物及其用作蛋白激酶抑制剂的方法，如对乳腺癌细胞、结肠癌细胞和卵巢癌细胞具有抗癌活性的TTK蛋白激酶、极化样激酶4（PLK4）和极化激酶。
• [EN] PROCESS FOR THE PREPARATION OF A DIASTEREOMERICALLY ENRICHED COMPOUND<br/>[FR] PROCEDE POUR LA PREPARATION D'UN COMPOSE ENRICHI EN DIASTEREOMERE
  申请人：DSM IP ASSETS BV

  公开号：WO2006008171A1

  公开（公告）日：2006-01-26

  The present invention relates to a process for the preparation of a diastereomerically enriched compound, wherein a first compound according to formula (I), is contacted with a second compound according to formula (II), to form a third compound according to formula (III), whereby the compound according to formula (III) is subsequently reduced and thereby converted into a compound according to formula (IV), in which formulas: R1= a cycloalkylgroup whereby R1 # R2, R2= a substituted or unsubstituted: (cyclo)alkyl group, (cyclo)alkenylgroup, aryl group, cyclic or acyclic heteroalkylgroup or heteroarylgroup, R3= an alkyl group, R4= a substituted or unsubstituted: phenyl- or naphthyl-group, *= a chiral center. The invention furthermore relates to a diastereomerically enriched compound according to formula (IV) and its use in the preparation of pharmaceutical and agrochemically active compounds. The invention further relates to a process for the preparation of enantiomerically enriched compounds of formula (V), through hydrogenolysis of diastereomerically enriched compounds of formula (IV), wherein R1 and R2 have the meanings given above.

  本发明涉及一种制备对映异构体富集化合物的过程，其中将式（I）的第一化合物与式（II）的第二化合物接触，形成式（III）的第三化合物，随后将式（III）的化合物还原，从而转化为式（IV）的化合物，其中式中：R1 = 环烷基，其中R1 ≠ R2，R2 = 取代或未取代的：（环）烷基，（环）烯基基团，芳基基团，环状或非环状杂基基团或杂环基团，R3 = 烷基，R4 = 取代或未取代的苯基或萘基，* = 手性中心。此外，本发明还涉及一种对映异构体富集化合物，其符合式（IV），以及其在制备制药和农业化学活性化合物中的应用。本发明还涉及一种制备式（V）的对映异构体富集化合物的过程，通过对式（IV）的对映异构体进行氢解，其中R1和R2具有上述含义。
• THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS
  申请人：Biju J. Purakkattle

  公开号：US20080090823A1

  公开（公告）日：2008-04-17

  Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

  本发明涉及的是一种新型的化合物，其结构式如下：其中包括Substituent A和Substituent B，其药学上可接受的盐和溶剂化合物。Substituent A的基团包括杂环芳基、芳基、杂环烷基、环烷基、炔基、烯基、氨基烷基、烷基或氨基。Substituent B的基团包括芳基和杂环芳基。本发明还涉及一种治疗趋化因子介导疾病的方法，例如癌症、血管生成、眼部血管生成性疾病、肺部疾病、多发性硬化症、类风湿性关节炎、骨关节炎、中风和缺血再灌注损伤、疼痛（例如急性疼痛、急性和慢性炎症性疼痛和神经病理性疼痛），使用化合物IA的方法。
• Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands
  申请人：Taveras G. Arthur

  公开号：US20070264230A1

  公开（公告）日：2007-11-15

  Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula IA.

  揭示了具有以下结构的新化合物：以及其药物可接受的盐和溶剂化物。包括取代基A的基团的例子包括杂环芳基，芳基，杂环烷基，环烷基，炔基，烯基，氨基烷基，烷基或氨基。包括取代基B的基团的例子包括芳基和杂环芳基。此外，还揭示了使用式IA的化合物治疗趋化因子介导的疾病的方法，例如，癌症，血管生成，血管生成性眼部疾病，肺部疾病，多发性硬化症，类风湿性关节炎，骨关节炎，中风和心脏再灌注损伤，急性疼痛，急性和慢性炎症性疼痛以及神经病理性疼痛。
• 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
  申请人：Taveras G. Arthur

  公开号：US20070021494A1

  公开（公告）日：2007-01-25

  There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

  公开了以下化合物的公式或其药学上可接受的盐或溶剂，它们可用于治疗趋化因子介导的疾病，如急性和慢性炎症性疾病和癌症。